Drug
CBL0137
CBL0137 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph early_phase_1
1
33%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
terminated133%
completed133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingearly_phase_1
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
NCT05498792
completedphase_1
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
NCT01905228
terminatedphase_1
Study of IV CBL0137 in Previously Treated Hematological Subjects
NCT02931110
Clinical Trials (3)
Showing 3 of 3 trials
NCT05498792Early Phase 1
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
NCT01905228Phase 1
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
NCT02931110Phase 1
Study of IV CBL0137 in Previously Treated Hematological Subjects
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3